Novartis AG ADR

NVS

New York Stock Exchange. Currency in USD

89.82 +0.26 ( +0.29% )

Real time prices: December 01

Market Cap.
193.20B
Beta (5Y monthly)
0.51
Price/Earnings
14.55
EPS (TTM)
6.00
Forward Dividend
3.33 (3.81%)
Ex-Dividend Date
Mar 09, 2022
Volume
1.48M
1y Target Est.
100.75
Day's Range
89.46
-
89.95
52 Week's Range
74.09
-
94.26

Historical Summary

Performance
EPS growth
Share Buybacks

About Novartis AG ADR

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.novartis.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
2.21B
Employees
108000
Address
Lichtstrasse 35, Basel, Switzerland, 4056
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Latest news

10 High-Yield Dividend Aristocrats For A Rolls Royce Retirement
10 High-Yield Dividend Aristocrats For A Rolls Royce Retirement

The 2022 bear market likely has another 16% to 28% lower to fall before it...
By Seeking Alpha - 1 day ago

Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?

Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should...
By Zacks Investment Research - 6 days ago

Novartis (NVS) Set to Advance Malaria Drug Into Phase III
Novartis (NVS) Set to Advance Malaria Drug Into Phase III

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of...
By Zacks Investment Research - 1 week ago

2 Top Biotech Stocks to Buy Right Now
2 Top Biotech Stocks to Buy Right Now

These two rank among the 10 largest pharmaceutical companies on the planet.
By The Motley Fool - 1 week ago

Novartis (NVS) Reportedly Looking to Sell Its Business Units
Novartis (NVS) Reportedly Looking to Sell Its Business Units

Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory...
By Zacks Investment Research - 2 weeks ago

Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines

Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's...
By Zacks Investment Research - 2 weeks ago

Should Income Investors Buy This High-Yielding Dividend Stock?
Should Income Investors Buy This High-Yielding Dividend Stock?

Novartis' product portfolio and pipeline bode well for its future.
By The Motley Fool - 2 weeks ago

Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates

Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its...
By Zacks Investment Research - 3 weeks ago